Basic HTML Version
123
SCIENTIFIC REPORT 2012
Title:
Evaluation of the safety of chronic oral administration of ivabradine formulation
modified release versus ivabridine immediate release formulation in patients with
stable coronary artery disease. Multicenter, randomized, double-blind study in
parallel groups, lasting 6 to 12 months.
District Attorney:
Servier Laboratories.
Principal Investigator:
Jordi Puntí Sala.
Title:
Open-label, pharmacokinetic and pharmacodynamic study, and tolerability of AVE5026
administered in weight-adjusted doses to patients under 18 years of age with a venous route
central (VVC).
District Attorney:
Sanofi-Aventis SA
Principal Investigator:
Silvia Sánchez Pérez.
Title:
Prevalence, clinical profile and therapeutic management of the patient with Ulcerative Colitis (UC) in
hospital gastroenterology services in Spain. EPICURE study.
District Attorney:
Abbott Laboratories SA
Principal Investigator:
Xavier Calvet Calvo
Title:
ALIGN-Transversal study, multinational to determine specific beliefs and
Patients' general information regarding medication and treatment compliance
selected systemic diseases for chronic inflammatory diseases (EIMI).
District Attorney:
Abbott Laboratories SA
Principal Investigator:
Xavier Calvet Calvo
Title:
Multicenter, randomized, double-blind, placebo-controlled, group study
parallel CP-690,550 orally as an induction treatment in patients with colitis
ulcerous between moderate and intense.
District Attorney:
Pfizer Inc.
Principal Investigator:
Valentí Puig Díví.
Title:
Multicenter, randomized, double-blind, placebo-controlled, group study
parallel CP-690.550 orally as a maintenance treatment in patients with
ulcerative colitis.
District Attorney:
Pfizer Inc.
Principal Investigator:
Valentí Puig Díví.